CNDO-109

N/A

Report date: 2022/09/06 18:03:10

Base Information

Drug NameCNDO-109

Drug Alias NameCNDO-109-AANK CellsCNDO-109-activated allogeneic NK cell therapyAllogeneic tumour activated natural killer lymphocytesCNDO-102CNDO-109

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionNatural killer cells stimulants

TargetsNot applicable

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity College London

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCoronado Biosciences Inc

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A